Inhibikase Therapeutics (IKT) Cash & Current Investments (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash & Current Investments data on file, last reported at $170.4 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 82.84% year-over-year to $170.4 million in Q1 2026; TTM through Mar 2026 was $170.4 million, a 82.84% increase from a year earlier, with the FY2025 full-year figure at $178.8 million, up 83.27% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $170.4 million, down from $178.8 million in the prior quarter.
• Over the last five years, Cash & Current Investments for IKT reached as high as $178.8 million in Q4 2025 and fell as low as $3.2 million in Q3 2024.
• Historically, Cash & Current Investments has averaged $54.2 million across 5 years, with a median of $26.5 million in 2022.
• Across the five-year window, Cash & Current Investments plunged 80.73% in 2024 and surged 2283.81% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $23.1 million in 2022, then tumbled by 42.51% to $13.3 million in 2023, then soared by 636.06% to $97.5 million in 2024, then jumped by 83.27% to $178.8 million in 2025, then dropped by 4.7% to $170.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $170.4 million in Q1 2026, $178.8 million in Q4 2025, and $77.3 million in Q3 2025.